Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
RESEARCH TOOLSreports
Anavex Life Sciences (AVXL) Stock Price & Analysis
1,174 Followers
AVXL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.81 - $15.24
Previous Close$6.97
Volume15.80K
Average Volume (3M)851.48K
Market Cap
$561.37M
Enterprise ValueN/A
Total Cash (Recent Filing)$154.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-10.6
Beta1.46
Next Earnings
Dec 12, 2023EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding81,951,115
10 Day Avg. Volume1,342,638
30 Day Avg. Volume851,484
Standard Deviation0.23
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.98
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$50.67Price Target Upside639.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Anavex Life Sciences News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $6.81 and its highest was $15.24 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Currently, no data Available
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Dec 12, 2023 which is in 81 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Aug 08, 2023. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.167 by $0.027.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -$0.15.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 81,951,120 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.167. Following the earnings report the stock price went up 4.557%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Among the largest hedge funds holding Anavex Life Sciences’s share is Sheaff Brock Investment Advisors LLC. It holds Anavex Life Sciences’s shares valued at 177K.
---
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.67 (639.71% Upside)
$50.67 (639.71% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 66%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.23%
12-Months-Change
Fundamentals
Return on Equity
-34.72%
Trailing 12-Months
Asset Growth
-1.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Anavex Life Sciences
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
---
Top 5 ETFs holding AVXL
Vanguard Total Stock Market ETF
$17.91M
Vanguard Health Care ETF
$2.24M
Schwab U.S. Broad Market ETF
$314.37K
Fidelity Nasdaq Composite Index ETF
$267.38K
Vanguard Russell 3000 ETF
$36.32K
Up to five ETFs with an Outperform Smart Score that hold AVXL. The ETFs are listed according to market value of AVXL within the ETF
Bioxcel Therapeutics
―
Cyclerion Therapeutics
―
Eton Pharmaceuticals
―
Frequency Therapeutics
―
---